União Europeia - inglês - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatic neoplasms - endocrine therapy - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer.- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

União Europeia - inglês - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - follitropin delta - anovulation - sex hormones and modulators of the genital system, - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

União Europeia - inglês - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - atosiban (as acetate) - premature birth - other gynecologicals - tractotile is indicated to delay imminent pre-term birth in pregnant adult women with:regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes;a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%;a gestational age from 24 until 33 completed weeks;a normal foetal heart rate.

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - follitropin delta - solution for injection - 33.33microgram/1ml

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - follitropin delta - solution for injection - 33.33microgram/1ml

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - follitropin delta - solution for injection - 33.33microgram/1ml

Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ferring gmbh - atosiban - solution for injection - 6.75mg/0.9ml

Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ferring gmbh - atosiban - concentrate for solution for infusion - 37.5mg/5ml

Canadá - inglês - Health Canada

apotex inc - naproxen (naproxen sodium, naproxen) - capsule - 200mg - naproxen (naproxen sodium, naproxen) 200mg - other nonsteroidal antiimflammatory agents

Estados Unidos - inglês - NLM (National Library of Medicine)

ther-rx corporation - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 20 mg in 1 g - clindesse is indicated for the treatment of bacterial vaginosis (formerly referred to as haemophilus vaginitis, gardnerella vaginitis, nonspecific vaginitis, corynebacterium vaginitis, or anaerobic vaginosis) in non-pregnant women. do not administer clindesse to individuals with a history of hypersensitivity to clindamycin or other lincosamides. reported reactions to other formulations of clindamycin include rashes, urticaria, erythema multiforme, and anaphylactoid reactions [see adverse reactions (6.2)] . do not administer clindesse to patients with regional enteritis, ulcerative colitis, or a history of clostridium difficile- associated diarrhea. pregnancy category b clindesse should be used during pregnancy only if clearly needed. there are no adequate and well-controlled studies of clindesse in pregnant women. another intravaginal formulation containing 2% clindamycin phosphate has been studied in pregnant women during the second trimester. in women treated for seven days, abnormal labor was reported i